Program - Society of Toxicology

Society of Toxicology 2011
Program Description (Continued)
Abstract #
Monday Afternoon, March 7
2:15 PM to 3:15 PM
Room 140B
Exhibitor Hosted Session: Nonhuman Primate (NHP) Infant
Age and Relevance of Postnatal and Juvenile Assessments:
Principles for Understanding Specific Endpoints in Study
Designs Supporting Biologics Regulatory Submissions
Presented by: SNBL USA, Ltd.
In regulatory-mandated NHP pre-/post-natal and juvenile studies, infant
development milestones and test compound pharmacology dictate the types
of parameters to monitor. The pertinent question is how to identify critical
parameters from the numerous possibilities that exist. This presentation will
highlight approaches to take and provide examples of background data and
interpretation.
Monday Afternoon, March 7
3:30 PM to 4:30 PM
Room 140B
Exhibitor Hosted Session: Announcing EPA’s Clean
Air Research Centers: Science to Protect Health in a
Multipollutant Atmosphere
Presented by: U.S. EPA
The U.S. Environmental Protection Agency is investing $32 million in new
Clean Air Research Centers (CLARCs). The CLARCs will investigate exposures
to air pollution mixtures, atmospheric transformation products, and
associated health outcomes to determine impacts across life stages, amongst
vulnerable populations, and within high-risk communities.
Monday Afternoon, March 7
3:30 PM to 4:30 PM
Room 140A
Exhibitor Hosted Session: Screening of Drug Candidates with
Idiosyncratic Hepatoxic Potential: Concepts and Approaches
Presented by: In Vitro ADMET Laboratories, LLC (IVAL)
Experimental assessment of idiosyncratic drug toxicity is elusive due to the
rarity of the events and the lack of appropriate animal models. The multiple
parameter hypothesis of idiosyncratic drug toxicity and promising experimental
approaches based on the hypothesis will be described.
Monday Afternoon, March 7
2:15 PM to 3:15 PM
Room 156
Exhibitor Hosted Session: Utility of Hematopoietic Colony
Forming Cell (CFC) Assays in Drug Development
Presented by: STEMCELL Technologies, Inc.
A potential side effect of anticancer and some antiviral/antimicrobial drugs
is damage to the hematopoietic (blood) system. Compounds that impair
cell proliferation and differentiation can result in neutropenia, anemia or
thrombocytopenia. This talk outlines the value of hematopoietic in vitro
clonogenic assays for prediction of hematotoxicity.
Abstract #
Monday Afternoon, March 7
3:00 PM to 4:00 PM
Room 103
Specialty Section Governance Group Meeting
Monday Afternoon, March 7
4:30 PM to 6:00 PM
Room 103
Specialty Section Presidents and Officers Meeting
If you will be a President or a Vice President of a Specialty Section in
2011–2012, please make plans to attend the Specialty Section Presidents
and Officers meeting. The agenda for the meeting will include an overview
of the SOT Strategic Plan, SOT Headquarters administrative support
information, ToXchange, a review of 2010–2011 activities and plans for
the future.
Monday Afternoon, March 7
4:35 PM to 5:55 PM
Room 150
SOT/EUROTOX Debate: Biomarkers from Blood
and Urine Will Replace Traditional Histopathological
Evaluation to Determine Adverse Responses
Chairperson(s): William Slikker, Jr., U.S. FDA, Jefferson, AR, and
Ruth Roberts, AstraZeneca, Macclesfield, United Kingdom.
SOT Debater: Kim Boekelheide, Brown University, Providence, RI.
EUROTOX Debater: Ina Schuppe Koistinen, AstraZeneca R&D
Södertälje, Södertälje, Sweden.
Endorsed by:
Society of Toxicology (SOT)
European Societies of Toxicology (EUROTOX)
Each year the SOT Annual Meeting includes a debate that continues a
tradition that originated in the early 1990s in which leading toxicologists
advocate opposing sides of an issue of great toxicological importance.
This year, our debaters will address the proposition: Biomarkers from
Blood and Urine Will Replace Traditional Histopathological Evaluation
to Determine Adverse Responses.
The strengths and limitations of histopathological and existing renal or
hepatic tests (BUN, ALT, etc.) have been examined over the years. These
endpoints may have advantages such as long term use but do they offer
sufficient potential for early detection and tissue specificity? And now
there exists a new generation of potential biomarkers spawned from the
promise of genomics, proteomics, metabolomics and imaging. Yet do the
data from these potentially minimally invasive, mechanistically-based
and time course endpoints provide information appropriate to define
adverse response? The debate will present some of the challenges that
researchers and regulators are facing in the development and integration
of new and existing biomarkers to determine adverse responses.
Regardless of framework differences and personal convictions, each
scientific delegate will present relevant evidence and compelling scientific
arguments to persuade and appeal to the response of the audience in
order to obtain the approval or refusal of the motion. In addition to being
a featured session at the SOT Annual Meeting, this debate will again take
place in Paris, France during the 2011 Eurotox Annual Congress, August
28–31, 2011.
MONday
Poster Sessions
Regional Interest Session
Roundtable Sessions
Symposium Sessions
Thematic Sessions
Workshop Sessions
191